CD8A and neoplasm: The number of tumor-infiltrating, cytotoxic Trp2-specific CD8+ T cells was higher (although not significantly) in PeptiCRAd VALO-mD901-Trp2-treated tumors compared to mock- or VALO-mD901-treated tumors.